CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0483 (clinicaltrials.gov NCT No: NCT00532259)
Title:STUDY CT-2007-01: Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients with Diffuse Large B-Cell Lymphoma following Autologous Stem Cell Transplantation
Principal Investigator:Chitra M. Hosing
Treatment Agent:CT-011 Monoclonal Antibody
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn how long CT-011 may be
able to keep DLBCL from returning when CT-011 is given to patients with DLBCL
after they have received autologous PBSCT and high-dose chemotherapy. The
safety of this treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Lymphoma
Phase of Study:Phase II
Treatment Agents:CT-011 Monoclonal Antibody
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:None
Supported By:CureTech Ltd.
Return Visit:Days 1, 2, 43, 85, week 1, 6, 9, 16, 30, 44, and 69
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Chitra M. Hosing
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults